Iboga and Bwiti

Bwiti among the Mitsogho and Apindji

The anthropologist Stanislaw Swiderski, writing in 1973 about the Fang of Gabon, states that the skull cult called Bouiti (Bwiti in most later sources) was founded by Pygmy peoples, developed by the Mitsogho and Apindji, and carried toward Lambarene and Libreville by Mitsogho workers who migrated for forestry and urban work. He places the Mitsogho and Apindji in the Ngounie region, between Fougamou, Mouila and Mimongo. The sources reviewed give no firm date for the origin of the Mitsogho form.

A 2025 study of traditional (non-syncretic) Bwiti describes it as widespread among at least twenty ethnic groups in Gabon, with the Mitsogho Bwete variant the most thoroughly studied. It names the Apindji, Eshira, Nkomi, Masango and Balumbu as other groups with more limited documentation.

Adoption and syncretism among the Fang

Swiderski reports that the Fang adopted Bouiti from Mitsogho migrants. He describes the early motives as individual: curiosity about seeing the beyond through visions that the iboga plant produces, followed over time by recognition of new social and religious values. He also describes the plant as a source of fraternity and clan cohesion. Oral tradition cited by Swiderski names a first Fang initiate near Libreville whose iboga initiation dated to about 1900.

Swiderski dates a spontaneous popular syncretic movement among the Fang to about 1920, mixing traditional cult elements with Christian ones and sparked by social disruption under colonial rule. He counts several dozen Bouitist and Ombwirist sects, each tracing to a founder's visions. The Ombwiri cult, in his account, was created by the N'Komi and Miene peoples. James Fernandez's 1982 ethnography likewise presents Bwiti as drawing on Fang culture after colonial contact, on missionary Christianity and on older Fang imagery.

Range of the plant and of the religion

Swiderski's 1973 footnote places the iboga shrub in the forests of Gabon, Equatorial Guinea, southern Cameroon and northern Congo. The 2006 Plant Resources of Tropical Africa entry gives a wider natural range from Cameroon through the Democratic Republic of Congo to Angola. The 2025 Bwiti study notes that little is documented about the spread of Bwiti in Equatorial Guinea, and the sources reviewed here do not document Bwiti practice in Cameroon.

From plant sacrament to extracted alkaloid

A 2018 chemical neuroscience review states that ibogaine was isolated from iboga and sold as an antidepressant in France for decades before adverse effects led to its withdrawal, and that US heroin users in the 1960s claimed it ended their opioid dependence. A 2023 review by Deborah Mash likewise dates public testimonials from American and European self-help groups to the 1960s. Thomas Kingsley Brown's 2013 review traces how addiction use developed largely outside conventional clinical settings.

Bwiti, Bouiti and Bwete

Swiderski's French-language scholarship uses Bouiti, while later English sources use Bwiti and use Bwete for the Mitsogho form. The term traditional Bwiti is used for forms not syncretic with Christianity, and syncretic Bwiti for Fang-led movements that combine traditional and Christian elements. Swiderski reports that initiates call the initiation a baptism by iboga, and he gives ebogha as the Galoa name of the plant.

Iboga, ibogaine and noribogaine

Iboga is the shrub Tabernanthe iboga, an understory plant of the Apocynaceae family that reaches about four meters in height. Ibogaine is its principal psychoactive alkaloid. Noribogaine, also called 12-hydroxyibogamine, is the metabolite that the body forms from ibogaine, mainly through the liver enzyme CYP2D6. Ibogaine for clinical and non-clinical addiction treatment may be extracted from the plant or made semisynthetically from the related alkaloid voacangine.

These terms are not interchangeable. Bwiti ceremonies use plant material, whereas clinical studies administer ibogaine hydrochloride. A 2012 review of deaths separately flags what it calls ethnopharmacological forms of ibogaine, meaning plant-derived preparations, as a risk when used without information.

Initiation and ceremony in outline

Sources describe iboga as a sacrament in Bwiti initiation and healing rituals. Swiderski notes that the plant is often cultivated near ritual houses and that syncretic sects use it as a communion. The Plant Resources of Tropical Africa entry says the root bark is eaten in large quantities during elaborate ceremonies to facilitate spiritual experience and communication with ancestors. This page stays at overview level and does not describe preparation, amounts or restricted initiation knowledge.

Reported effects

Swiderski lists mild tremors, numbness, nausea, vomiting and weakness, with a raised heart rate and dilated pupils, together with visual and auditory distortions and emotional experiences that participants interpret within religious faith. A 2025 psychometric study of 499 people treated in two clinical settings identified seven dimensions of the ibogaine experience, including narrative and symbolic visions, cosmic or archetypal visions, discomfort and challenge, and dissociation.

Ibogaine in clinical and non-clinical settings

A 2012 forensic review states that ibogaine is used globally in medical and nonmedical settings for opioid detoxification and other substance use indications. A Dutch open-label study gave ibogaine to patients in a university psychiatry department with repeated cardiac monitoring, while earlier series by Alper and colleagues describe treatment in nonmedical settings. A 2023 review by Mash estimates that more than ten thousand people have sought ibogaine treatment, a figure presented as an estimate.

Within Bwiti

Bwiti sources attribute several purposes to iboga use: initiation into the religion, communication with ancestors, communal healing and social cohesion. Faura and colleagues describe it as a communal binding practice that treats individual struggles through collective ritual. Fernandez analyzes Bwiti as a means of reconciling past and present for Fang people under colonial change. Mash and colleagues state that indigenous peoples use low doses against fatigue, hunger and thirst, which the sources reviewed do not otherwise corroborate.

In addiction treatment

Self-help groups in the 1960s reported that a single ibogaine dose eased drug craving and opioid withdrawal and helped prevent relapse for weeks to years, according to Mash's 2023 review. Brown's 2013 review notes that preclinical research has generally supported these anecdotal claims but that a lack of solid human data has slowed development. These claims come from the addiction literature and are not part of Bwiti belief.

Ceremonial use

No controlled or observational health study of Bwiti ceremonial use was found. A PubMed search for iboga with Bwiti, run on 2026-10-06, returned four records, none of them a study of ceremonial practice. The ethnographic sources by Swiderski and Fernandez are descriptive and do not test outcomes. Evidence about ibogaine in addiction settings should not be carried over to ceremonial use, or the reverse.

Open-label and observational ibogaine studies

Alper and colleagues' 1999 case series summarized 33 opioid detoxification treatments in nonmedical settings under open-label conditions. Withdrawal signs resolved without further drug seeking within 24 hours in 25 patients, sustained through 72 hours of observation, and one fatality possibly involved heroin use. Mash and colleagues reported decreased craving for cocaine and heroin during inpatient detoxification and lower depressive symptoms at 30 days.

Brown and Alper's observational study followed 30 adults with opioid dependence for 12 months. Withdrawal scale scores fell from 31.0 to 14.0, and at one month 15 participants (50 percent) reported no opioid use in the previous 30 days. Noller and colleagues followed 14 people for 12 months, with 8 completing all interviews, and reported lower drug use and depression scores; one enrolled patient died during treatment. One author of that study was employed by an organization that funds psychedelic research. None of these studies had a comparison group.

Reviews and what remains uncertain

A 2023 systematic review of substance use disorder studies selected 31 articles and concluded that ibogaine shows some efficacy, particularly in opioid detoxification, while describing its cardiotoxicity and mortality as worrying. A 2025 systematic review covering several psychedelics identified five ibogaine studies with 166 participants and judged the best evidence of efficacy to lie with psilocybin and ketamine for alcohol use disorder. A 2026 review refers to observational, open-label and limited randomized placebo-controlled trials; no randomized trial was verified for this page. Small samples, missing controls and loss to follow-up limit these findings.

Harvest and supply

The Plant Resources of Tropical Africa entry states that wild plants are usually uprooted, causing large-scale destruction of natural stands, whereas harvesting from home gardens takes only part of the roots. It adds that no germplasm collections exist, so extensive wild harvesting threatens genetic diversity. Faura and colleagues, writing in 2020, describe wild iboga as endangered by improper harvesting and poaching and cite community cultivation projects such as the Ebyeng-Edzuameniene association in Gabon. Swiderski had earlier noted cultivation near ritual houses. The sources reviewed give no verified figure for population decline.

Commercialization and benefit sharing

Faura, Langlois and Bouso, who work for a research and education organization active in this area, argue that pharmaceutical extraction separates ibogaine from the knowledge systems and ecology in which iboga is used and treats the plant as a commodity. They call for reciprocal models that return benefits to source communities and ecosystems. This is the authors' position, presented here as an attributed view rather than an established finding.

Cardiac effects

Ibogaine blocks the hERG potassium channel, which helps the heart reset between beats. In laboratory cells, ibogaine, noribogaine and voacangine blocked the channel at low micromolar concentrations, and the authors link noribogaine's long half-life to QT prolongation and arrhythmia days after ingestion. A 2016 toxicology review describes QT prolongation, ventricular arrhythmias and sudden cardiac arrest, including eight case reports in people without known cardiovascular disease or family history.

In a Dutch open-label study of 14 patients monitored for at least 24 hours, the average maximum QTc prolongation was 95 ms (range 29 to 146 ms), half of participants exceeded 500 ms, and in six the QTc stayed above 450 ms beyond 24 hours. No torsades de pointes occurred. A 2026 review calls the cardiac risk rare but clinically significant and notes wide variation in CYP2D6 metabolism between individuals.

Reported deaths

Alper, Stajic and Gill reviewed all known fatalities outside West Central Africa linked in time to ibogaine from 1990 through 2008 and found 19 deaths, 1.5 to 76 hours after ingestion. In 12 of 14 cases with adequate postmortem data, preexisting medical conditions, mainly cardiovascular, or other substances explained or contributed to the death. They saw no characteristic neurotoxic syndrome and named withdrawal seizures from alcohol and benzodiazepines as another apparent risk factor. The 2016 toxicology review counts 27 reported fatalities. The sources give no death rate, because the number of people exposed is unknown.

Other harms, interactions and suitability

All 14 patients in the Dutch study developed severe transient ataxia that prevented walking unaided. The 2023 systematic review found headache to be a significant risk. Because CYP2D6 variation changes ibogaine and noribogaine levels, the 2016 review warns about interaction with other medicines that this enzyme handles. That review adds that rats showed cerebellar neurodegeneration at higher doses, of uncertain relevance to people.

The sources reviewed contain no safety data specific to Bwiti ceremonies. The 2016 toxicology review describes treatment with iboga extracts, root scrapings or ibogaine with limited medical supervision as risky, particularly for people with cardiac conditions or on other medications, and the 2026 review recommends controlled medical supervision with cardiac monitoring. Ibogaine does not replace necessary medical or addiction care.